1. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
- Author
-
Javier Escudero, Victoria Heredia-Soto, Yinyin Wang, Patricia Ruiz, Yingying Hu, Alejandro Gallego, Jose Juan Pozo-Kreilinger, Virginia Martinez-Marin, Alberto Berjon, Eduardo Ortiz-Cruz, Daniel Bernabeu, Jaime Feliu, Jing Tang, Andres Redondo, Marta Mendiola, Research Program in Systems Oncology, Faculty of Medicine, and Medicum
- Subjects
Cancer Research ,3122 Cancers ,Proliferation ,TUBULIN ,MESYLATE ,PHASE-2 ,03 medical and health sciences ,0302 clinical medicine ,Invasion ,Genetics ,MESILATE ,Eribulin ,SYNERGY ,RC254-282 ,Migration ,030304 developmental biology ,0303 health sciences ,QH573-671 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,SITE ,Sarcoma ,CANCER ,3. Good health ,Oncology ,2D and 3D models ,030220 oncology & carcinogenesis ,Cytology ,Primary Research - Abstract
Background Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been approved for advanced liposarcoma (LPS). Methods In this study, we evaluated the effect of eribulin on proliferation, migration and invasion capabilities in LPS, leiomyosarcoma (LMS) and fibrosarcoma (FS) models, using both monolayer (2D) and three-dimensional (3D) spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the treatment of STS with the aim of increasing its antitumour activity. Results Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line models. Furthermore, we provide data that suggest, for the first time, a synergistic effect with ifosfamide in all models, and with pazopanib in LMS as well as in myxoid and pleomorphic LPS. Conclusions Our results support the effect of eribulin on LPS, LMS and FS cell line models. The combination of eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.
- Published
- 2021